VYNE Therapeutics Inc — Cash Flow (NASDAQ:VYNE) | MetaTrader

Open full chart

Financials

Overview Отчетность Statistics Dividends

Quarterly Annual

Cash from operating activities -137.08 M-56.37 M-29.2 M-25.34 M-33.97 M33.12 M — Cash from investing activities 89.11 M1.03 M15.67 M-57.35 M23.36 M37.37 M — Cash from financing activities 61.81 M39.78 M1.65 M82.39 M-141 K143 K — Free cash flow -137.19 M-56.37 M-29.2 M-25.34 M-34.09 M33.12 M —

Новости

VYNE Therapeutics объединится с Yarrow Bioscience в сделке на $200 млн

VYNE Therapeutics to merge with Yarrow Bioscience in $200 million deal

VYNE Therapeutics Inc. (VYNE) Yarrow Bioscience, Inc. - M&A Call Prepared Remarks Transcript

Акции Vyne Therapeutics взлетели после слияния с Yarrow Bioscience

Vyne Therapeutics stock soars after merger with Yarrow Bioscience

VYNE и Yarrow Bioscience объединяются в сделке с оплатой акциями

VYNE and Yarrow Bioscience to merge in all-stock transaction

Crude Oil Rises Over 1%; General Mills Earnings Top Views - DBV Technologies (NASDAQ:DBVT), General Mills (NYSE:GIS)

Dow Jumps 150 Points; Jabil Posts Upbeat Earnings - Aditxt (NASDAQ:ADTX), Agape ATP (NASDAQ:ATPC)

VYNE Therapeutics Inc. (VYNE) Reports Q3 Loss, Tops Revenue Estimates

VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Lags Revenue Estimates

Metagenomi (MGX) Reports Q2 Loss, Tops Revenue Estimates